Appendix of Amendments

12. (Three Times Amended) A pharmaceutical composition comprising [a D- or L-tryptophanyl-ester or its] an N-acyl derivative of a D- or L-tryptophanyl-ester for the prophylaxis and/or therapy of oxidative pathologic processes in degenerative and/or cancer diseases having the following formula:



wherein X is $C(O)R_1$ [or H], and R_1 is a saturated C_1 [C2]-C_{18} [carbon hydrogen] hydrocarbon residue and R_2 is a saturated or unsaturated C_2-C_{18} [carbon hydrogen] hydrocarbon residue, and a pharmaceutically acceptable carrier, alone or in combination with a second therapeutic compound.

16. (Amended) The pharmaceutical composition according to claim 12, wherein the [D- or L-tryptophanyl-ester or its] N-acyl derivative is selected from the group consisting of

[tryptophanoctyl-ester, tryptophandodecyl-ester, tryptophanstearyl-ester, tryptophanpalmityl-ester, tryptophanoleyl-ester,] N-acetyl-tryptophanoctyl-ester, N-acetyl-tryptophandodecyl-ester, N-acetyl-tryptophanstearyl-ester, N-acetyl-tryptophanpalmityl-ester, N-acetyl-tryptophanoleyl-ester, N-dodecanoyl-tryptophanoctyl-ester, N-dodecanoyl-tryptophandodecyl-ester, N-dodecanoyl-tryptophanstearyl-ester, N-dodecanoyl-tryptophanpalmityl-ester, N-dodecanoyl-tryptophanoleyl-ester, N-acetyl-tryptophanethyl-ester, N-hexoyl-tryptophanethyl-ester, N-octoyl-tryptophanethyl-ester, N-dodecanoyl-tryptophanethyl-ester, N-stearoyl-tryptophanethyl-ester[,] and N-palmitoyl-tryptophanethyl-ester [and N-oleoyl-tryptophanethyl-ester].

17. (Amended) The pharmaceutical composition according to claim 12, wherein the [D- or L-tryptophanethyl-ester or its N-acetyl] N-acyl derivative is an N-acetyl derivative and is selected from the group consisting of [tryptophanoctyl-ester, N-oleoyl-tryptophanethyl-ester and] N-dodecanoyl-tryptophanethyl-ester.

18. (Amended) A pharmaceutical composition comprising [a D- or L-tryptophanyl-ester or its] an N-acyl derivative of a D-

or L-tryptophanyl-ester, wherein the [D- or L-tryptophanyl-ester or its] N-acyl derivative has the following formula:



wherein X is $C(O)R_1$ [or H], and R_1 is a saturated C_1 [C2]-C_{18} or unsaturated C_2-C_7 [carbon hydrogen] hydrocarbon residue and R_2 is a saturated or unsaturated C_9-C_{18} [carbon hydrogen] hydrocarbon residue, and a pharmaceutically acceptable carrier.

19. (Amended) The pharmaceutical composition according to claim 18, wherein the [D- or L-tryptophanyl-ester or its] N-acyl derivative is selected from the group consisting of [tryptophanstearyl-ester, tryptophanpalmityl-ester, tryptophanoleyl-ester,] N-acetyl-tryptophandodecyl-ester, N-acetyl-tryptophanstearyl-ester, N-acetyl-tryptophanpalmityl-ester, N-acetyl-tryptophanoleyl-ester, N-dodecanoyl-tryptophanoctyl-ester, N-dodecanoyl-tryptophandodecyl-ester, N-dodecanoyl-tryptophanstearyl-ester, N-dodecanoyl-

tryptophanpalmityl-ester, N-dodecanoyl-tryptophanoleyl-ester, N-hexoyl-tryptophanethyl-ester, N-octoyl-tryptophanethyl-ester, N-dodecanoyl-tryptophanethyl-ester, N-stearoyl-tryptophanethyl-ester and N-palmitoyl-tryptophanethyl-ester.

20. (Amended) The pharmaceutical composition according to claim 18, wherein the [D- or L-tryptophanethyl-ester or its N-acetyl] N-acyl derivative is N-dodecanoyl-tryptophanethyl-ester.

23. (Amended) The pharmaceutical composition according to claim 12 or 21, wherein the second therapeutic compound is selected from the group consisting of ciliary neurotropic factor (CNTF), aniracetam, buflomedil, choline, co-dergocrine, cyclandelate, desferrioxamine, eptastigmine, fampridine, galantamine, isoxusuprine, lecithin, linopiridine, metriphonate, naftidrofuryl, nicergoline, nicotine, nimodipine, oxiracetam, physostigmine, pilocarpine, piracetam, pramiracetam, propentofylline, pyritinol, RS-86, selegiline, suronacrine, tacrine, velnacrine, somatomedines, protirelin, an immunoglobulin and an [immunosuppressiva] immunosuppressive.